ResearcherThe Cancer Institute HospitalActive in the last 2 years
Sho Kiritani
Matched on OpenAlex author ID A5006787206, A5072308467. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers
Papers 6
- Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futile pancreatectomy. Co-author DOI 10.1016/j.hpb.2025.12.021↗
- Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease? Co-author DOI 10.1245/s10434-025-18511-2↗
- Unique Biology of Pancreatic Ductal Adenocarcinoma Accompanied by Rapidly Impaired Diabetes: A Favorable Long-Term Survival Following Curative Resection. Co-author DOI 10.1245/s10434-023-14408-0↗
- Radical Antegrade Modular Pancreatosplenectomy for Left-Sided Pancreatic Ductal Adenocarcinoma May Reduce the Local Recurrence Rate. Co-author DOI 10.1159/000524927↗
- Diabetogenic liver metastasis from pancreatic cancer: a case report. Co-author DOI 10.1186/s40792-022-01582-8↗
- High-performance Collective Biomarker from Liquid Biopsy for Diagnosis of Pancreatic Cancer Based on Mass Spectrometry and Machine Learning. Co-author DOI 10.7150/jca.63244↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kiyoshi Hasegawa · 3 shared papers, 2022–2026 · strength 0.73
- Paper Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease? DOI 10.1245/s10434-025-18511-2↗
- Paper Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futil… DOI 10.1016/j.hpb.2025.12.021↗
- Paper Radical Antegrade Modular Pancreatosplenectomy for Left-Sided Pancreatic Ductal Adenocarcinoma May Reduce the Local Rec… DOI 10.1159/000524927↗
- Yusuke Kazami · 2 shared papers, 2026 · strength 0.55
- Paper Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease? DOI 10.1245/s10434-025-18511-2↗
- Paper Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futil… DOI 10.1016/j.hpb.2025.12.021↗
- Satoru Abe · 2 shared papers, 2026 · strength 0.55
- Paper Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease? DOI 10.1245/s10434-025-18511-2↗
- Paper Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futil… DOI 10.1016/j.hpb.2025.12.021↗
- Takeshi Takamoto · 2 shared papers, 2026 · strength 0.55
- Paper Large Resectable Pancreatic Cancer is Associated with Futile Surgery: A Resectable But Not Curable Disease? DOI 10.1245/s10434-025-18511-2↗
- Paper Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futil… DOI 10.1016/j.hpb.2025.12.021↗
- Yosuke Inoue · 2 shared papers, 2022–2024 · strength 0.37
- Manabu Takamatsu · 2 shared papers, 2022–2024 · strength 0.37
- Atsushi Oba · 2 shared papers, 2022–2024 · strength 0.37
- Hiromichi Ito · 2 shared papers, 2022–2024 · strength 0.37
- Yu Takahashi · 2 shared papers, 2022–2024 · strength 0.37
- Kazunaga Ishigaki · 1 shared paper, 2026 · strength 0.26
- Naminatsu Takahara · 1 shared paper, 2026 · strength 0.26
- Tatsunori Suzuki · 1 shared paper, 2026 · strength 0.26
- Mitsuhiro Fujishiro · 1 shared paper, 2026 · strength 0.26
- Yoshihiro Ono · 1 shared paper, 2024 · strength 0.20
- Akio Saiura · 1 shared paper, 2024 · strength 0.20
- Takeaki Ishizawa · 1 shared paper, 2022 · strength 0.19
- Yoshihiro Ono · 1 shared paper, 2022 · strength 0.16
- Ryo Saito · 1 shared paper, 2021 · strength 0.12
- Genki Watanabe · 1 shared paper, 2021 · strength 0.12
- Tomohiko Iwano · 1 shared paper, 2021 · strength 0.12
- Daisuke Ichikawa · 1 shared paper, 2021 · strength 0.12
- Hiromichi Kawaida · 1 shared paper, 2021 · strength 0.12
- Sén Takeda · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.